The Product Development for Vaccines Advisory Committee (PDVAC) provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies. Its remit includes the prioritisation of target pathogens for vaccine and/or monoclonal antibody development and technology platforms, in addition to oversight of the development of preferred product characteristics (PPCs), technical/R&D roadmaps, full vaccine value assessments and consultations on product development pathways.
The 2023 meeting took place over the 12th and 13th December 2023
Day 1 - Tuesday 12th December 2023: Presentations (compiled by session)
Context for and goals of this PDVAC meeting - Birgitte Giersing
IA2030 and the SP7 Research and Innovation Update - Kwaku Poku Asante
Regional engagement strategy to identify IA2030 global priority endemic pathogens - Mateusz Hasso-Agopsowicz
Vaccine development and manufacturing priorities in the Africa region - Martin Friede; Abebe Genetu Bayih; Yalda Momeni
Combination Vaccines and the vaccine value proposition - Bill Hausdorff
Gavi Vaccine Investment Strategy - Marta Tufet
Overview of the PDVAC and vaccine product delivery research (PDR) unit activities in 2023 - WHO PDR secretariat
Vaccine specific sessions introduction - Marco Cavaleri
Group B Strep - Kirsty Le Doare; David Goldblatt
Chikungunya vaccines - Annelies Wilder-Smith; Susan Hills; Henrik Salje; Tim Endy; Robin Levis
Shigella vaccines - Bill Hausdorff; Cal MacLennan; Rob Kaminski
Day 2 - Wednesday 13th December 2023: Presentations (compiled by session)
New tuberculosis vaccines - Sonali Kochhar; Willem Hanekom; Mark Hatheril; Birgitte Giersing; Velislava Petrova
New malaria vaccines - Mary Hamel; Lindsey Wu; Ashley Birkett; Patrick Duffy
Salmonella vaccines - Adwoa Bentsi-Enchill; Kate Emary; Andy Pollard; Jean Louis Excler
Overview of progress in STI vaccines - Carolyn Deal
Therapeutic HPV vaccines (tHPV) - Sami Gottlieb; Peter Dull
Update on MR-MAP (measles and rubella vaccines on microarray patches) - Mateusz HassoAgopsowicz; Courtney Jarrahian; Darin Zehrung